UNSPSC 51382405: Bromfenac sodium sesquihydrate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate but more generally known as bromfenac sodium, which bears US NIH Compound Identifier 60725. European Medicines Agency schedules Bromfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00874MIG.

Most nations, for tariff and trade purposes, schedule bromfenac sodium sesquihydrate under HS 29225000. SMILES: C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].C1CC(C(C(C1)C(=O)C2CCC(CC2)BR)N)CC(=O)[O-].O.O.O.[NA+].[NA+].

UNSPSC 51382405 Bromfenac sodium sesquihydrate is a Commodity code that in recent state and local procurement appears misaligned with its nominal pharmaceutical-chemical scope. The three most recent opportunities posted under or near this code involve naloxone kits and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which center on bromfenac sodium sesquihydrate, a nonsteroidal anti-inflammatory ophthalmic agent. The issuing bodies span a county health department (Seminole County, Florida), a state health commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), reflecting the fragmented nature of pharmaceutical procurement across different governance tiers and purchasing vehicles. The code does not show evidence of recent activity specifically targeting bromfenac sodium sesquihydrate procurement by state or local agencies.

The geographic footprint of recent opportunities covers Florida, Texas, and Minnesota through MMCAP's multi-state participation including Oregon. Seminole County issued an IFB (Solicitation IFB60459723LAS) posted June 30, 2026, with a response deadline of July 26, 2023, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to its community health building. Texas HHS Commission issued an RFI (HHS0017013) posted April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. Minnesota's MMCAP released an RFP (S1070000015802) posted January 20, 2026, with a March 26, 2026, response deadline, for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers and effective July 1, 2026. The code shows little relevant recent activity aligned with bromfenac sodium sesquihydrate as a discrete procurement target; opportunities tagged under or near the code address broader pharmaceutical categories, bulk naloxone distribution, and multi-state cooperative drug purchasing rather than specific ophthalmic pharmaceutical agents.